Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?

Shares of Amgen (AMGN 0.02%) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period. The clear culprit for the drop is, quite regrettably for shareholders, an unintentional disclosure of clinical trial information that the market found to be rather unappetizing.But does that change the investment thesis for buying the stock, or is it just a blip?This revelation is e ...